Jacob Neidhardt
STOCKHOLM, SWEDEN – December 18, 2024
Swedish medtech company Corsmed has raised $3.5 million in seed funding to advance its groundbreaking digital twin MRI technology, reducing scan times from 45 minutes to just 2–3 minutes. The funding round, co-led by Luminar Ventures and Big Pi Ventures, brings Corsmed’s total investment to $10 million.
Transforming Preventive Healthcare with Faster, Cheaper MRI
The high cost and lengthy duration of traditional MRI scans have historically limited their role in preventive healthcare. Corsmed aims to change that with its software, which generates high-resolution, full 3D brain contrasts ten times faster than conventional methods. Additionally, Corsmed’s technology provides quantitative MRI (qMRI), delivering measurable, standardized data across timeframes and patients, enhancing diagnostic precision and enabling broader accessibility.
Erik Jacobsson, CEO of Corsmed, emphasized:
“We’re working toward a future where routine, whole-body scans can detect diseases like cancer at their earliest stages, giving everyone a fair shot at a long and healthy life. Our technology bridges the gap between today’s reactive ‘sick-care’ system and a true healthcare model.”
Key Features and Market Impact
• Speed and Accessibility: Corsmed’s software works with existing MRI hardware, reducing scan costs and increasing patient throughput, making advanced imaging more accessible.
• Improved Training Tools: Corsmed’s MRI simulator, used by over 50 institutions including The Christie NHS Foundation Trust and UCLH, has saved more than 80,000 hours of live scanner time while training medical staff in a low-pressure environment.
• Global Applications: The technology has potential for public hospitals worldwide, pending FDA approval in the U.S. and HIPAA compliance.
Investor Confidence in Preventive Imaging
Magnus Bergman, co-founding partner at Luminar Ventures, stated:
“Democratizing MRI scans will save thousands of lives daily by making early detection of life-threatening conditions both affordable and widespread. Corsmed’s innovative qMRI technology is at the forefront of this shift.”
Nick Kalliagkopoulos, Partner at Big Pi Ventures, added:
“Corsmed has the potential to redefine global healthcare with its blend of innovation and accessibility. This funding marks a crucial step in unlocking preventive and personalized health solutions.”
Next Steps
Corsmed plans to apply for FDA approval in 2025 and scale its qMRI solutions globally, focusing on reducing diagnostic bottlenecks in healthcare systems. With a mission to make MRI scans a standard tool in preventive care, Corsmed is set to transform the medtech landscape.
For more information, visit Corsmed.
Media Contact:
Email: [email protected]
Location: Stockholm, Sweden
